The user has been using finasteride, minoxidil, and a derma stamp for 3 months with significant improvement. They are now adding ketoconazole to their routine.
Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.
Hair regrowth using estradiol, spironolactone, minoxidil, and finasteride, showing significant improvement over four years. HRT is not advised for cis men solely for hair loss due to feminizing effects.
Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.
A naturally occurring sugar, 2-deoxy-D-ribose, in a hydrogel form, shows promise for hair regrowth similar to minoxidil in rats. The user plans to synthesize it for topical application, seeking input from others.
The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.
Exosome therapy for hair loss is questioned for its effectiveness and authenticity. Users express skepticism, citing manipulated photos and high costs.
A 30-year-old MTF individual shared a 6-month update on hair loss improvement using minoxidil, retinol, and microneedling, along with lowering testosterone to reduce DHT. They reported positive results, feeling happier and more confident.
The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.
The user is using topical minoxidil and finasteride with good results and is considering adding stemoxydine 5% to their regimen. Another user suggests trying it if financially feasible, as results can vary.
A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.
A user shared their experience using capsaicin from chili peppers and occasional topical minoxidil to promote hair growth, noting noticeable improvements without significant side effects. They previously experienced side effects from dutasteride and minoxidil but found the new regimen effective and manageable.
The conversation discusses the potential benefits of Sulforaphane for hair growth, with a suggestion to grow broccoli sprouts for the best results. One user doubts its effectiveness for hair loss but notes its anti-cancer and hormetic benefits.
A 20-year-old male experienced significant hair regrowth and reduced shedding after four months of using 2.5mg oral minoxidil, 1mg oral finasteride, and weekly 1.5mm derma stamping. He reported no side effects from the treatments and noted increased hair growth in other areas of his body.
Mixing topical finasteride with essengen f and stemoxydine creates 0.25mg dose in 2ml. Minoxidil max suggests mixing 8.5ml essengen f with 60ml solvent for 0.25mg dose in 1ml.
A 37-year-old reported significant hair regrowth and increased confidence after two years of using oral finasteride and topical minoxidil, with no side effects. They are satisfied with the results and are reconsidering the need for a hair transplant.
Minoxidil sulfate is considered for those unresponsive to regular minoxidil, with some trying a 10% formulation from Folligenz. Concerns exist about the product's stability and transparency, but some users report positive initial results.
The user experiences irritation from alcohols in minoxidil and is considering alternatives like trichosol mixed with polyethylene glycol or DMSO. They seek advice on the best nonirritating option.
The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.
The conversation discusses how applying topical tretinoin for 5 days can convert 43% of individuals who initially do not respond to minoxidil into responders, enhancing the effect of minoxidil on hair growth. Specific treatments mentioned are minoxidil and tretinoin.
The user is using topical finasteride, Bioscalin, Omega 3, and hair filler therapy for hair loss. There is some progress noted, but varying photo angles and lighting make it hard to assess fully.
Oral minoxidil is more effective than topical for some users, increasing hair density and thickness. Lack of response to topical minoxidil may be due to insufficient sulfotransferase enzyme, which can be upregulated with tretinoin.
The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.
A user shared progress pictures one year after a hair transplant with 2,000 grafts on the crown area. They use topical minoxidil and finasteride daily, along with biotin supplements.
Korean scientists developed a red light therapy that reduces a hair loss marker by 92%. Users discussed the benefits and drawbacks of natural sunlight versus red light caps for hair health, with some suggesting supplements for vitamin D.
A 21-year-old male with advanced hair loss (NW7) started using finasteride and minoxidil 10 months ago but hasn't seen much progress. He is pre-diabetic with stage 1 hypertension and is seeking insights on whether treating these conditions could improve hair regrowth.
A user underwent a 3750 graft hair transplant in Turkey, initially promised 4500 grafts, and is satisfied with the results despite some concerns about donor site size and crown coverage. The user has been on medications like finasteride and minoxidil for about four months and may consider a second transplant in the future.
A user who underwent a hair transplant in Istanbul to reduce balding, and the discussion of various treatments such as finasteride and growth hormone for preventing further hair loss.
Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.